Therapeutic efficacy and dose-limiting toxicity of auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model

International Journal of Cancer

Volumn 76, Issue 5, 1998, Pages 738-748

  Behr, Thomas M ^a   Sgouros, George ^b   Vougioukas, Vassilios ^a   Memtsoudis, Stavros ^a   Gratz, Stefan ^a   Schmidberger, Heinz ^a   Blumenthal, Rosalyn D ^c   Goldenberg, David M ^c   Becker, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c GARDEN STATE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY I 125; MONOCLONAL ANTIBODY I 131;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUGER ELECTRON SPECTROSCOPY; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CANCER TRANSPLANTATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BETA RAYS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRONS; FEMALE; HUMANS; IMMUNOTOXINS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031750281     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980529)76:5<738::AID-IJC20>3.0.CO;2-Z     Document Type: Article

References (45)

1. 131I-monoclonal antibody A33. Proc. Amer. Ass. Cancer Res., 34, 477 (abstract 2844) (1993).
2. 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J. nucl. Med., 36, 430-441 (1995a).
3. BEHR, T.M., GOLDENBERG, D.M. and BECKER, W.S., Radioimmunotherapy of solid tumors: a review "Of Mice and Men". Hybridoma, 16, 101-107 (1997a).
4. BEHR, T.M., SHARKEY, R.M., JUWEID, M.E., BLUMENTHAL, R.D., DUNN, R.M., BAIR, H.J., GRIFFITHS, G.L., WOLF, F.G., BECKER, W.S. and GOLDENBERG, D.M., Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res., 55, 3825-3834 (1995b).
5. BEHR, T.M., SHARKEY, R.M., JUWEID, M.E., DUNN, R.M., SIEGEL, J.A. and GOLDENBERG, D.M., Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J. nucl. Med., 38, 409-418 (1997b).
6. BEHR, T.M., SHARKEY, R.M., JUWEID, M.E., DUNN, R.M., VAGG, R.C., YING, Z., ZHANG, C.H., SWAYNE, L.C., SIEGEL, J.A. and GOLDENBERG, D.M., Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anticarcinoembryonic antigen murine monoclonal antibody IgG. J. nucl. Med., 38, 858-870 (1997c).
7. BEHR, T.M., SHARKEY, R.M., SGOUROS, G., BLUMENTHAL, R.D., DUNN, R.M., KOLBERT, K., GRIFFITHS, G.L., SIEGEL, J.A., BECKER, W.S. and GOLDENBERG, D.M., Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer, 80, 2591-2610 (1997d).
8. BEHR, T.M., WULST, E., RADETZKY, S., BLUMENTHAL, R.D., DUNN, R.M., GRATZ, S., RAVE-FRÄNK, M., SCHMIDBERGER, H., RAUE, F. and BECKER, W., Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin polentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res., 57, 5309-5319 (1997e).
9. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res., 52, 121-126 (1992).
10. BLUMENTHAL, R.D., SHARKEY, R.M., FORMAN, D., WONG, G., HESS, J. and GOLDENBERG, D.M., Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp. Hematol., 23, 1088-1097 (1995).
11. BLUMENTHAL, R.D., SHARKEY, R.M., HAYWOOD, L., BEHR, T. and GOLDENBERG, D.M., Application of cytokine intervention for improved radioantibody dose delivery. Int. J. Cancer, 72, 166-173 (1997).
12. 125I treatment of thyrotoxicosis. Clin. Endocrinol., 5, 225-234 (1976).
13. 3HTdR. Radiat. Res., 67, 332-343 (1976).
14. DAGHIGHIAN, F., BARENDSWAARD, E., WELT, S., HUMM, J., SCOTT, A., WILLINGHAM, M.C., MCGUFFIE, E., OLD, L.J. and LARSON S.M., Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled monoclonal antibody J. nucl. Med., 37, 1052-1057 (1996).
15. DESOMBRE, E.R., SHAFII, B., HANSON, R.N., KUIVANEN, P.C. and HUGHES, A., Estrogen receptor-directed radiotoxicity with Auger-electrons: specificity and mean lethal dose. Cancer Res., 52, 5752-5758 (1992).
16. DUNCAN, J.R., BEHR, T.M. and DENARDO, S., Intracellular fate of radiometals. J. nucl. Med., 38, 829 (1997).
17. FEINENDEGEN, L.E., Biological damage from Auger effect, possible benefits. Radiat. Environ. Biophys., 12, 85-99 (1975).
18. FURHANG, E.E., SGOUROS, G. and CHUI, C.S., Radionuclide photon dose kernels for internal emitter dosimetry. Med. Phys., 23, 759-764 (1996).
19. GODDU, S.M., HOWELL, R.W. and RAO, D.V., Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J. nucl. Med., 35, 303-316 (1994).
20. GODDU, S.M., HOWELL, R.W. and RAO, D.V., Generalized approach to absorbed dose calculations for dynamic tumor and organ masses. J. nucl. Med., 36, 1923-1927 (1995).
21. GOLDENBERG, D.M., WITTE, S. and ELSTER, K., GW-39: a new human tumor serially transplantable in the golden hamster. Transplantation, 4, 760-764 (1966).
22. GÖTTLINGER, H.G., FUNKE, I., JOHNSON, J.P., GOKEL, J.M. and RIETHMÜLLER, G., The epithelial surface antigen 17-1A, a target for antibody-mediated tumour therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int. J. Cancer, 38, 47-53 (1986).
23. HERLYN, M., STEPLEWSKI, Z., HERLYN, D. and KOPROWSKI, H., Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc. natl. Acad. Sci. (Wash.), 76, 1438-1442 (1979).
24. HERLYN, M., STEPLEWSKI, Z., HERLYN, D. and KOPROWSKI, H., CO17-1A and related monoclonal antibodies: their production and characterization. Hybridoma, 5 (Suppl. 1), S3-S10 (1986).
25. HOEFNAGEL, C.A., SMETS, L., VOUTE, P.A. and DE KRAKU, J., Iodine-125-MIBG therapy for neuroblastoma. J. nucl. Med., 32, 361-362 (1991).
26. 125I on mouse and rat thyroid. Int. J. Radiat. Biol., 22, 489-499 (1972).
27. 125I-labeled monoclonal antibody 17-1A against human colon carcinoma. Proc. Amer. Ass. Cancer Res., 35, 648 (abstract 3863) (1994).
28. KASSIS, A. and ADELSTEIN, S.J. (eds.), Radiolabeled IUdr. J. nucl. Med., 37 (Suppl.), 1S-32S (1996).
29. KOPROWSKI, H., STEPLEWSKI, Z., MITCHELL, K., HERLYN, M., HERLYN, D. and FUHRER, J.P., Colorectal carcinoma antigens detected by hybridoma antibodies. Somat. Cell Genet., 5, 957-972 (1979).
30. 125I-antibody therapy efficacy in multicell spheroids. Cancer Res., 52, 4728-4734 (1992).
31. LINZ, U. and STÖCKLIN, G., Chemical and biological consequences of the radioactive decay of iodine-125 in plasmid DNA. Radiat. Res., 101, 262-278 (1985).
32. LITVINOV, M., VELDERS, M.P., BAKKER, H.A.M., FLEUREN, G.J. and WARNAAR, S.O., Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol., 125, 437-446 (1994).
33. MARTIN, R.F. and HASELTINE, W.A., Range of radiochemical damage to DNA with decay of iodine-125. Science, 213, 896-898 (1981).
34. MEREDITH, R.F., KHAZAELI, M.B., PLOTT W.E., SPENCER, S.A., WHEELER R.H., BRADY, L.W., WOO, D.V. and LOBUGLIO, A.F., Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J. nucl. Med., 36, 2229-2233 (1995).
35. 125I-bovine serum albumin. Radiat. Res., 133, 182-186 (1993).
36. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet, 346, 336-340 (1995).
37. RAO, D.V., SASTRY, S.R., GOVELITZ, G.F., GRIMMOND, H.E. and ZILL, H.Z., Radiobiological effects of Auger electron emitters in vivo: spermatogenesis in mice as an experimental model. Radiat. Prot. Dosim., 13, 245-248 (1985).
38. SASTRY, K.S.R. and RAO, D.V., Dosimetry of low energy electrons. In: D.V. Rao, R. Cnandra and M.C. Graham (eds.), Physics of nuclear medicine: recent advances, pp. 169-208. American Institute of Physics, American Association of Physicists in Medicine, Medical Physics Monograph, Woodbury, NY, 10 (1984).
39. SGOUROS, G., Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. nucl. Med., 34, 689-694 (1993).
40. SHARKEY, R.M., BLUMENTHAL, R.D., BEHR, T.M., WONG, G.Y., HAYWOOD, L., FORMAN, D., GRIFFITHS, G.L. and GOLDENBERG, D.M., Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int. J. Cancer, 72, 477-485 (1997).
41. SHARKEY, R.M., NATALE, A., GOLDENBERG, D.M. and MATTES, M.J., Rapid blood clearance of immunoglobulin G2a in nude mice. Cancer Res., 51, 3102-3107 (1991).
42. VELDERS, M.P., VAN RHIJN, C.M., BRIAIRE, I.H., FLEUREN, G.J., WARNAAR, S.O. and LITVINOV, S.V., Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res., 55, 4398-4403 (1995).
43. 125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. Cancer Res., 56, 5428-5434 (1996).
44. WELT, S., SCOTT, A.M., DIVGI, C.R., KEMENY, N.E., FINN, R.D., DAGHIGHIAN, F., ST. GERMAIN, J., RICHARDS, E.C., LARSON, S.M. and OLD, L.J., Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. clin. Oncol., 14, 1787-1797 (1996).
45. 125I-labeled monoclonal antibody 17-1a in human cancer cells. Cancer Res., 49, 2952-2958 (1989).